FDA clears Inovio to begin mid-stage testing of its Covid-19 vaccine candidate, but one hurdle remains
November 16, 2020 at 09:14 AM EST
The decision sent the Plymouth Meeting biotechnology company's stock up nearly 14% to $12.75 per share in premarket trading.
